Pharmaceuticals
News Releases
2022 April
Pharmaceuticals
Otsuka and Ai-BrainScience Announce Sales Collaboration Agreement for New Cognitive Function Testing Application That Uses Eye Tracking Technology
Corporate
Otsuka Group Joins RE100 International Initiative - Committed to 100% Renewable Energy -
Pharmaceuticals
Osaka University and Otsuka Pharmaceutical to Enter into an Exclusive License Agreement on New Anti-tumor Antibody
2022 March
Pharmaceuticals
Akebia Therapeutics Receives Complete Response Letter from U.S. FDAfor Vadadustat for the Treatment of Anemia associated with Chronic Kidney Diseasein Adult Patients
Pharmaceuticals
Otsuka Subsidiary to Receive Payment and Royalties from Approval in U.S. ofRadioligand Therapy for Metastatic Castration-Resistant Prostate Cancer- Out-licensed by ABX in Germany, an indirectly-owned subsidiary of Otsuka Pharmaceutical -
Pharmaceuticals
Otsuka Obtains Approval in Japan for SAMTASU® for I.V. Infusion, a V2 -Receptor Antagonist for the Treatment of Cardiac Edema
Corporate
Packaging for a Sustainable FuturePOCARI SWEAT to Introduce Recycled PET for Bottles from Spring 2022
Corporate
Otsuka Pharmaceutical Appointments of Board Members and Statutory Auditors (PDF: 58.8 KB)
Nutraceuticals
～Otsuka Pharmaceutical Survey of "Working Women's Health Consciousness"～ Indication that women’s health concerns (PMS, menopause) significantly affect career paths. Need for recognition as "corporate issues" beyond individual efforts.
Nutraceuticals
Introducing New Calorie Mate BLOCK VanillaNutritional Balance in Everyday Life for People of All Ages
2022 February
Nutraceuticals
Otsuka Extends Its Deep Expertise in Soy-Based Products to Launch SOYJOY 100% Plant-Based Series
Corporate
Favorable Judgment on Lawsuit on Patent Right Held in Relation to Otsuka Pharmaceutical Foods Containing Equol
Corporate
Otsuka Pharmaceutical Certified as Sports Yell Company for 5th Consecutive Year- Collaboration among Otsuka Group Companies to Support Employees' Ongoing Fitness Efforts -
2022 January
Pharmaceuticals
Otsuka Enters Agreement with Jolly Good for Co-Development and Sales Rights in Japanfor a Social Skills Training Platform Using Virtual Reality in the Psychiatric Field
Corporate
Favorable judgment on lawsuit for revocation of trial decision on patent right held in relation to equol-containing foods
Pharmaceuticals
Otsuka and Lundbeck Announce U.S. FDA Approval of Supplemental New Drug Application for REXULTI® (brexpiprazole) to Treat Schizophrenia in Pediatric Patients
2021 December
2021 November
Nutraceuticals
Launch of tocoelle Supplement - Gentle support for pre-menstrual fluctuations -
Pharmaceuticals
Announcement of Termination of Co-Development and Exclusive Marketing Agreements with Takara Bio for Oncolytic virus HF10 and CD19-Targeted CAR Gene Therapies
Corporate
Otsuka Group Supports Recommendations of the Task Force on Climate-related Financial Disclosure (TCFD) -Joins TCFD Consortium-
Pharmaceuticals
Otsuka Measurement Kit to Assist in Diagnosis and to Monitor Treatment Effectiveness for Acute Lymphoblastic Leukemia (ALL), to be Covered by Health Insurance in Japan
2021 October
Pharmaceuticals
Otsuka submits initial marketing authorization application to the European Medicines Agency for vadadustat for the treatment of adults with anemia associated with chronic kidney disease
Pharmaceuticals
Otsuka Announces Approval in EU of Pediatric, 25 mg Dispersible-Tablet Formulation of Deltyba™ for Multidrug-Resistant Tuberculosis
2021 September
Pharmaceuticals
Sumitomo Dainippon Pharma and Otsuka Announce a Worldwide Collaborationand License Agreement for Four Psychiatry and Neurology Compounds
Pharmaceuticals
Otsuka's Moizerto® Ointment Granted Approval in Japan as a Treatment for Atopic Dermatitis
Pharmaceuticals
Otsuka announces that Novartis Pharma's ENTRESTO® received a new indication for treatment of hypertension in Japan
Corporate
100th Anniversary of Otsuka Group of Companies Looking Ahead to the Next 100 Years
2021 August
Pharmaceuticals
Otsuka to Launch AJOVY® Subcutaneous Injection 225 mg Syringe in Japan
Pharmaceuticals
Busulfex Injection 60mg Approved in Japan for Once-daily Administration in Pediatric Patients
Pharmaceuticals
Otsuka Obtains Approval in Japan for Orally-Disintegrating-Dose Form of REXULTI® Tablets
Pharmaceuticals
Otsuka reports topline outcomes on a phase II trial that evaluated brexpiprazole for the treatment of borderline personality disorder
Nutraceuticals
Otsuka Pharmaceutical Responds to New Lifestyles with Measures for Prevention of Heat Disorders at National Junior High School Championships 2021Supporting safe extracurricular sports activities and event operation
Pharmaceuticals
Otsuka Awarded Grant for Phase 2 Trial Combining Novel Anti-Tuberculosis Compound OPC-167832 with Delamanid and Bedaquiline
Nutraceuticals
Production and Sales of Fibe-Mini Begin in Indonesia
2021 July
Nutraceuticals
Reflecting Customer Concerns Introduction of ORONAMIN C DRINK in Label-free Bottles
Nutraceuticals
U.S. Supplement Brand Nature Made Marks 50th Anniversary/Named #1 Pharmacist Recommended Vitamin and Supplement for 24 Years
Nutraceuticals
Otsuka Pharmaceutical Responds to New Lifestyles with Measures for Prevention of Heat Disorders at Inter-High 2021 Supporting safe operation and health of competitors and officials for summer Inter-High School Championships
Nutraceuticals
Pharmavite, a U.S. subsidiary of Otsuka Pharmaceutical, acquires Uqora, a provider of women's urinary tract health products
Pharmaceuticals
Otsuka Files Application in Japan for Approval of Auto-Injector Dosage Form for AJOVY® Subcutaneous Injection 225 mg for Preventive Treatment of Migraine
Pharmaceuticals
Otsuka Pharmaceutical and Shanghai Rightongene AnnounceCollaboration to Commercialize WT1 mRNA Assay Kit in China
2021 June
Pharmaceuticals
Otsuka Obtains New, High-Sensitivity Biomarker Measurement Technology- Technology using surface plasmon field-enhanced fluorescence spectroscopy -
Pharmaceuticals
Otsuka Has Filed a Marketing Authorization Application to the European Medicines Agency for Voclosporin for the Treatment of Patients with Lupus Nephritis
Pharmaceuticals
AJOVY® Subcutaneous Injection 225 mg Syringe, as a Preventive Treatment of Migraine, Granted Approval in Japan
Pharmaceuticals
Approval in Japan for Otsuka's minor BCR-ABL mRNA measurement kit A marker to monitor treatment effectiveness for acute lymphoblastic leukemia (ALL)
Pharmaceuticals
Quick NaviTM - Flu+COVID-19 Ag Receives Regulatory Approval in Japan as a Combo, Rapid Diagnostic Kit for Influenza and COVID-19- Simultaneous testing for both viruses using a single test sample -
Corporate
Otsuka Group Complete Introduction of CO2-free Electricity for All 23 Manufacturing Facilities in Japan -Contributing to a more than 40% reduction in annual CO2 emissions in Japan-
Pharmaceuticals
Otsuka and Akebia Announce U.S. FDA Acceptance for Filing of New Drug Application for Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease
2021 April
Corporate
Otsuka Group Company, A&P Inphatec, Commences Sales in U.S. of XylPhi-PD™,a Bactericidal Treatment for Pierce's Disease in Grapevines
Corporate
Otsuka Pharmaceutical Receives First Certification as Tokyo Metropolitan Government Sports Promotion Model Company (Practical Division) Recognized for providing opportunities for exercise adapted for new lifestyles
Pharmaceuticals
Otsuka and Lundbeck announce decision to continue phase III clinical trial evaluating brexpiprazole for treatment of agitation in patients with Alzheimer's-type dementia
2021 March
Pharmaceuticals
Otsuka and Akebia Announce Submission of New Drug Application to the FDA for Approval of Akebia's Vadadustat
Pharmaceuticals
Otsuka to Launch QuickNaviTM-H.pylori, a Helicobacter pylori Quick Detection Kit- Test results in eight minutes and stool collection tools provided in one pack -
Pharmaceuticals
Otsuka Has Filed an Application in Japan for Regulatory Approval of OPC-61815, a V2 -Receptor Antagonist for the Treatment of Cardiac Edema
Pharmaceuticals
New Drug Application for Oral Disintegrated Tablet Formulation of TAKECAB® for Treatment of Acid-Related Disease
Pharmaceuticals
Otsuka and Perception Neuroscience Announce Collaboration on Development of PCN-101 (R-ketamine) in Japan for Treatment of Depressive Disorders
Corporate
Otsuka Pharmaceutical Appointments of Board Members and Statutory Auditors (PDF: 57.4 KB)
Nutraceuticals
A Delicious Snack That's Good for You Announcing SOYJOY Coffee & Nuts Soy protein from low-GI whole soy
2021 February
Nutraceuticals
Convenient Sizes of UL·OS Medicated Scalp Shampoo and Medicated Skin Wash Launched to Promote Trial Use
Corporate
Otsuka to Construct a Drug Discovery Center in Osaka Prefecture, Japan
Corporate
Office Divisions of Five Otsuka Group Companies to Switch to Green Power
Pharmaceuticals
Otsuka and Illumina Announce Agreement on Development and Commercialization of IVD Test Kit for Patients in Japan with Blood Cancer
Corporate
Otsuka Pharmaceutical Certified as Sports Yell Company for 4th Consecutive Year -Providing Opportunities for Exercise Tailored for New Lifestyles-
2020 December
2020 November
2020 October
Pharmaceuticals
Quick NaviTM Rapid Diagnostic Test in Japan Now Supports Simultaneous Testing for Influenza and COVID-19 Through Collection of a Single Testing Sample
Nutraceuticals
Debut of InnerSignal Skin Care Brand Outside Japan - Launched in South Korea as Functional Cosmetics with Two Key Benefits -
Pharmaceuticals
Otsuka and its subsidiary Astex announce results of phase 3, ASTRAL-2 and ASTRAL-3 trials of guadecitabine in patients with previously treated AML and MDS/CMML
Pharmaceuticals
Positive Top-Line Results in Phase 3 Trial of OPC-61815, a V2 -Receptor Antagonist for the Treatment of Cardiac Edema
Pharmaceuticals
Quick NaviTM-COVID 19 Ag Rapid Diagnostic Test in Japan Now Enables Test Sample Collection from Front of Nasal Cavity
2020 September
Corporate
Otsuka Group Acquires ISO 14001 Certification -Reinforcement of group-wide environmental initiatives-
Pharmaceuticals
Otsuka Has Filed an Application in Japan for Approval of Difamilast (OPA-15406) as an Atopic Dermatitis Drug
Pharmaceuticals
Otsuka's ABILIFY MAINTENA approved for the additional indication of bipolar I disorder in Japan
Nutraceuticals
- Creating a Society that Supports Ongoing Employee Health - Full-scale launch of "Kenko Shacho" community website connecting corporate leaders
Nutraceuticals
Smart Nutrition for New Lifestyles Announcing SOYJOY Green Tea & Macadamia Moist Texture Highlights the Mellow Astringency and Savor of Green Tea
Nutraceuticals
Otsuka Pharmaceutical Supports High School Students in Summer 2020 Supporting events across Japan that are close to their hearts, including alternative athletic competitions
Pharmaceuticals
Top-line Results from Global Phase 3 Program of Vadadustat, a Drug Candidate for Treatment of Renal Anemia due to Chronic Kidney Disease in Non-Dialysis Patients
2020 August
Pharmaceuticals
Novartis Pharma and Otsuka to Launch Entresto® Tablets in Japan for Patients with Chronic Heart Failure
Pharmaceuticals
Otsuka to Co-market New Diagnostic Test for COVID-19, Quick Navi-COVID 19 Ag-Confirmation of test results in just 15 minutes, and easy-to-read results shown in two contrasting colors-
2020 July
2020 June
Pharmaceuticals
Novartis Pharma obtains manufacturing and marketing approval in Japan for Entresto® tablet as angiotensin receptor neprilysin inhibitor (ARNI) for chronic heart failure
Pharmaceuticals
Samsca®approved in Japan for additional indication of hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion (SIADH)
Pharmaceuticals
Otsuka Pharmaceutical and Axcelead Drug Discovery Partners announce joint research in CNS indications
Pharmaceuticals
Clinical program for NY-ESO-1/siTCRTM gene therapy candidate receives designation in Japan as Orphan Regenerative Medicine
Pharmaceuticals
Japan's MHLW grants Sakigake Designation to comprehensive genomic profiling assay for hematologic malignancies co-developed by Otsuka
Nutraceuticals
Introduction of Set of Heat Disorder-related Teaching Materials: "Get Back That Sweat! Preventing Heat Disorders Together"
Pharmaceuticals
Launch of a New Combination Ophthalmic Solution for the Treatment of Glaucoma and Ocular Hypertension, AILAMIDE® Combination Ophthalmic Suspension
Pharmaceuticals
Otsuka Announces Positive Top-line Results from Two Phase 3 Studies of Centanafadine for the Treatment of Attention-deficit Hyperactivity Disorder (ADHD) in Adult Patients
2020 May
Pharmaceuticals
Deltyba® (delamanid) approved in Russian Federation for treatment of pulmonary multidrug-resistant tuberculosis (MDR-TB)
Pharmaceuticals
Launch of Aspirin/Vonoprazan Fumarate Combination Tablets: "Cabpirin® Combination Tablets"
Pharmaceuticals
Positive Top-Line Results from Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis
2020 April
Corporate
Otsuka Pharmaceutical to use CO2-free electricity at all plants in Japan (PDF: 96.4 KB)
Nutraceuticals
Research on the Relationship Between Hair Problems and Capacity to Produce Equol
Pharmaceuticals
Otsuka Enters into Licensing Agreement in Japan for Bempedoic Acid, a Treatment for Hypercholesterolemia
Pharmaceuticals
Otsuka to Introduce QuickNaviTM-Adeno2, an Adenovirus Quick Measurement Kit- Faster and clearer test results with two contrasting colors -
2020 March
Pharmaceuticals
Development of the first comprehensive genomic profiling assay for hematologic malignancies in Japan- Consortium of major Japanese hospitals and Otsuka Pharmaceutical start a project to evaluate its clinical utility -
Pharmaceuticals
Otsuka Announces Top-line Results from Two Phase 3 Studies in Japan for Atopic Dermatitis Drug Candidate Difamilast (OPA-15406)
Pharmaceuticals
Otsuka's Busulfex Receives Additional Indication in Japan as a Conditioning regimen Prior to Autologous Hematopoietic Stem Cell Transplantation for Malignant Lymphoma
Pharmaceuticals
Cabpirin® Combination Tablet Receives Regulatory Approval in Japan for Treatment of Acid-related Diseases in Patients Needing Low-dose Aspirin
Nutraceuticals
Dietary Education App "SketchCook" Recognized with Ministry of Education, Culture, Sports, Science and Technology（MEXT） "Award for Companies Promoting Experience-based Learning Activities for Youth 2019"
Nutraceuticals
Newly published findings on inhibitory effect of near-infrared (IRA) radiation on human epidermal cell proliferation and potential mechanisms
Corporate
Otsuka Pharmaceutical Reappointments and New Appointments of Board Members and Statutory Auditors (PDF: 57.4 KB)
Nutraceuticals
Introducing InnerSignal Rejuvenate ONE－All-in-One Skin Care Product with Time-Lapse Penetration Combines Lightening and Three Basic Skin Care Functions－
Pharmaceuticals
Otsuka enters into co-promotion agreement for angiotensin receptor neprilysin inhibitor (ARNI) LCZ696 in Japan
2020 February
Pharmaceuticals
First-of-its-kind global collaboration launched to develop transformative treatment regimens for tuberculosis
Pharmaceuticals
Otsuka Pharmaceutical Establishes Subsidiary in Malaysia
Nutraceuticals
Introducing New UL·OS Face & Body Sheet A single sheet provides convenient facial and body care
Nutraceuticals
Launch of "Health Support Plus" Service to manage workforce health based on desknet's NEO groupware
Nutraceuticals
Whole soy nutrition bar delivers the same satisfying crunchy texture with a significant reduction in sugars SOYJOY Peanuts Renewal Launch
Pharmaceuticals
Otsuka Pharmaceutical and the Japan Kidney Association Form Collaborative Agreement -Aim to identify practical uses of basic research in the kidney field-
Pharmaceuticals
Otsuka announces that subsidiary Astex Pharmaceuticals' NDA for ASTX727 (oral C-DEC), for the treatment of MDS and CMML, has been accepted for priority review by the U.S. FDA
Nutraceuticals
Tokyo Marathon 2020 - Connecting With the World Otsuka Pharmaceutical to be an Official Partner for 14th consecutive year
2020 January
Nutraceuticals
Otsuka Pharmaceutical Establishes Health Beverage Subsidiary in Mexico
Pharmaceuticals
Otsuka announces positive top-line results from clinical trials in Japan offremanezumab as a prophylactic treatment for migraine
Corporate
Otsuka Pharmaceutical Awarded Grand Prize in Tokyo Metropolitan Government Women's Participation Awards for First Year of the Reiwa Era
Pharmaceuticals